Frontlight ResearchEarly access
Liver and biliary tract cancer trials in China
130 of 621 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- No phaseNot yet taking people in China90Y-SIRT as Conversion Therapy for Unresectable Hepatocellular Carcinoma
- Where
- Beijing, Chongqing, Fuzhou, Guangzhou, Shenyang, Xi’an
- Age
- 18 years and over
- People
- 200
- Run by
- Beijing Tsinghua Chang Gung Hospital
See details and how to joinNCT07942025 - No phaseTaking peopleMultimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer
- Where
- Shanwei
- Age
- 18 years to 80 years
- People
- 2,000
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT07880106 - No phaseTaking peoplePeripheral Blood Biomarkers and Response to Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma
- Where
- Shanghai
- Age
- 18 years to 80 years
- People
- 100
- Run by
- Shanghai Zhongshan Hospital
See details and how to joinNCT07734857 - No phaseTaking peopleAnatomic Versus Nonanatomic Liver Resection After Conversion Therapy for Hepatocellular Carcinoma
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 874
- Run by
- Sun Yat-sen University
See details and how to joinNCT07927452 - No phaseNot yet taking people in ChinaIntegration of Imaging, Molecular, Pathological, and Clinical Outcome Data in Hepatocellular Carcinoma.
- Where
- Chengdu
- Age
- 18 years and over
- People
- 380
- Run by
- West China Hospital
See details and how to joinNCT07912853 - No phaseTaking peopleAblation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma
- Where
- Beijing
- Age
- 18 years to 80 years
- People
- 470
- Run by
- Sun Yat-sen University
See details and how to joinNCT06644430 - No phaseTaking peopleAdjuvant Immune Checkpoint Inhibitors in Postoperative Hepatocellular Carcinoma
- Where
- Nanning
- Age
- 18 years to 75 years
- People
- 10,000
- Run by
- Guangxi Medical University
See details and how to joinNCT05221398 - No phaseTaking peopleSurgery vs. Watch-and-Wait Strategy in Partial & Complete Responders for Hepatocellular Carcinoma
- Where
- Chengdu
- Age
- 18 years to 80 years
- People
- 100
- Run by
- West China Hospital
See details and how to joinNCT07410715 - No phaseTaking peopleInstaSure™ Non-Invasive Finger-Press Test for Hepatocellular Carcinoma
- Where
- Beijing
- Age
- 18 years and over
- People
- 40
- Run by
- Beijing Municipal Administration of Hospitals
See details and how to joinNCT07848750 - No phaseTaking peopleA Prospective Real-World Observational Study of Intratumoral Oncolytic Virus Injection Combined With Immune Checkpoint Inhibitors for Metastatic Tumors (Colorectal Cancer, Gastric Cancer, and Hepatocellular Carcinoma)
- Where
- Guangdong
- Age
- 18 years to 75 years
- People
- 30
- Run by
- Jie Yuan,MD
See details and how to joinNCT07850882 - No phaseTaking peopleMultimodalomics-based Construction of Spatiotemporal Characteristics of Dynamic Liver Cancer Microenvironment to Characterize the Clinical Application of Immune Mechanisms in Liver Cancer
- Where
- Wuhan
- Age
- 18 years to 80 years
- People
- 400
- Run by
- Tongji Hospital
See details and how to joinNCT07838415 - No phaseTaking peopleBiomarker Validation for Treatment Efficacy and Recurrence Prediction in Hepatocellular Carcinoma
- Where
- Tianjin
- Age
- 18 years and over
- People
- 500
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07840092 - No phaseNot yet taking people in ChinaTACE in Combination With Tislelizumab and Lenvatinib for Advanced HCC (CHANCE2602)
- Where
- Nanjing
- Age
- 16 years and over
- People
- 596
- Run by
- Zhongda Hospital
See details and how to joinNCT07836309 - No phaseTaking peopleMultimodal Survival Prediction Model for Colorectal Liver Metastases Post-Operation
- Where
- Hefei
- Age
- 18 years to 80 years
- People
- 205
- Run by
- Anhui Provincial Hospital
See details and how to joinNCT07830576 - No phaseNot yet taking people in ChinaHeterogeneity of Treatment Effects of Adding Locoregional Therapies to Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma (ISMIO-026)
- Where
- Nanjing
- Age
- 18 years and over
- People
- 2,658
- Run by
- Zhongda Hospital
See details and how to joinNCT07824765 - No phaseTaking peopleA Cohort Study (Risk Prediction of HCC in Patients With Chronic Liver Disease)
- Where
- Shenzhen
- Age
- 18 years to 75 years
- People
- 15,000
- Run by
- Cai Qingxian
See details and how to joinNCT07820644 - No phaseTaking peopleEffect of Laparoscopic Hepatectomy Combined With Splenectomy on Hepatic Functional Reserve and Immune Function
- Where
- Yangzhou
- Age
- 18 years to 80 years
- People
- 30
- Run by
- Northern Jiangsu People's Hospital
See details and how to joinNCT07811687 - No phaseTaking peopleProstate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients
- Where
- Hefei, Qingdao, Tianjin
- Age
- 18 years to 80 years
- People
- 500
- Run by
- Tianjin Medical University
See details and how to joinNCT06690970 - No phaseNot yet taking people in ChinaHCC Risk Prediction Model Based on Multimodal Data in Chronic Hepatitis B
- Where
- Beijing
- Age
- 18 years and over
- People
- 2,000
- Run by
- Beijing Friendship Hospital
See details and how to joinNCT07780357 - No phaseTaking peopleLiver Volume Metrics for Predicting Immunotherapy Prognosis in Unresectable Hepatocellular Carcinoma
- Where
- Hefei
- Age
- 18 years to 75 years
- People
- 467
- Run by
- Anhui Provincial Hospital
See details and how to joinNCT07782632 - No phaseTaking peopleDigital Early Warning System for Acute Lung Injury in Liver Surgery
- Where
- Beijing, Chongqing, Qingdao
- Age
- 18 years and over
- People
- 3,000
- Run by
- Beijing Tsinghua Chang Gung Hospital
See details and how to joinNCT07070362 - No phaseTaking peopleIntelligence System for Predicting Atezolizumab-Bevacizumab Response and Clinical Outcomes in Unresectable Hepatocellular Carcinoma
- Where
- Wenzhou
- Age
- 18 years and over
- People
- 400
- Run by
- First Affiliated Hospital of Wenzhou Medical University
See details and how to joinNCT07495735 - No phaseNot yet taking people in ChinaThe Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
- Where
- Guangzhou, Harbin, Kunming, Nanning, Qingdao, Shanghai
- Age
- 18 years and over
- People
- 400
- Run by
- Shanghai Zhongshan Hospital
See details and how to joinNCT07724951 - No phaseTaking peopleTACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for HCC
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 120
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT07658833 - No phaseTaking peoplePrediction Model for MINS After Major Hepatobiliary Surgery
- Where
- Beijing, Chongqing, Qingdao, Shandong, Zhuhai
- Age
- 18 years to 85 years
- People
- 1,800
- Run by
- Beijing Tsinghua Chang Gung Hospital
See details and how to joinNCT07335042